Superworth

Nuwellis NUWE

Medical - Devices, Healthcare
$5.18
−8.80%
Market cap
$2.1M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
0.2×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$9M
+8% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−599.7%

Nuwellis trades at 0.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $9M over the last twelve months, up 8% on a year earlier.

Charts

Financials

Income statement for NUWE, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$2.4M+17%$2.6M+9%$1.9M+2%$2.2M+6%$2.4M−2%$2.3M−9%$1.9M+3%$1.7M−21%$2.2M−6%$2.4M+4%$2.4M+26%$2M+14%
Cost of revenue$1M+28%$1.2M+15%$666K−12%$720K−22%$711K−31%$967K−17%$837K+26%$767K+7%$772K+9%$770K−20%$719K−14%$471K−39%
Gross profit$1.4M+10%$1.4M+4%$1.2M+12%$1.5M+29%$1.7M+20%$1.4M−2%$1.1M−10%$958K−35%$1.4M−13%$1.7M+22%$1.7M+58%$1.5M+56%
R&D$1.1M+20%$1.4M+14%$1.3M−7%$558K−63%$486K−57%$831K−39%$550K−59%$675K+21%$603K+24%$884K+6%$1.7M+214%$942K+40%
SG&A$3.4M−19%$3.6M−23%$4.6M−16%$3.2M−31%$2.7M−21%$2.9M−19%$3.6M−22%$3.2M−2%$3.5M+31%$3.2M+10%$4.5M+27%$3.7M+17%
−$3.2M−19%−$3.6M−21%−$4.7M−19%−$2.3M−54%−$1.5M−52%−$2.4M−34%−$3.1M−36%−$2.9M+25%−$2.7M+76%−$2.4M+2%−$4.6M+49%−$3.2M+9%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income−$3.4M−13%−$5.5M+191%−$4.3M−33%−$7.7M+60%$2.4M−$1.5M−73%−$3M−30%−$12.5M+63%$468K−80%−$2.4M+65%−$4.5M+51%−$4.8M−62%
$2K+0%$2K−33%$2K+0%$2K+0%$0$1K−50%$1K−50%$4K+100%$0$0$0$0
Net income−$3.4M−13%−$5.5M+191%−$4.3M−33%−$7.7M+59%$2.4M−$1.5M−73%−$3M−30%−$12.6M+63%$468K−80%−$2.4M+65%−$4.5M+51%−$4.8M−62%
−$837062.10−95%−$1042127.10−55%−$318975.30−88%−$249423.30−85%$23067.45−$5821.20−99%−$9112.95−97%−$19207.71−92%$176.40−99%−$475.65−92%−$689.85−92%−$239.76−99%
4+1676%8+832%14+458%31+980%650+16042%253+3232%331+2335%653+2010%2.7K+309%5.1K+1909%6.6K+1892%20.1K+2982%

Gross profit: 19 periods, Q2 FY16 to Q4 FY20: not printed by the filing, worked out from its own lines.

Net income: 25 periods, Q1 FY11 to Q1 FY17: not printed by the filing, worked out from its own lines.

EPS, diluted: 13 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 13 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x30).

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Nuwellis' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
NUWENuwellis$2.1Mn/mn/a0.2×+8%n/m
OXBROXBRIDGE RE HOLDINGS$6.5M40.2×9.8×2.4×+40%4.7%
EDUCEducational Development$8.9M5.5×11.3×0.4×−32%8.6%
GTIMGood Times Restaurants$14M6.3×13.5×0.1×−6%1.7%
MDRRMedalist Diversified$17.9M2.9×3.0×1.9×−1%80.2%
VIPVulcan Infrastructure & Power$18.4M16.7×22.5×0.4×−14%1.0%
BCGBinah Capital$18.6M6.8×20.0×0.1×+8%2.2%
MXCMexco Energy$19.2M12.5×13.3×2.8×−9%23.3%
ATCHAtlasClear$20.6M13.6×16.7×1.0×+85%9.8%
Peer median$18.1M9.7×13.4×0.7×−3%6.7%

More on Nuwellis

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Devices
Sector
Healthcare

Valuation data, not investment advice. Prices as of .